Diagnosis of laryngeal carcinoma

Jovanović, Milan B.

doi:10.2298/mpns0812591j

Cited by 7 publications

(5 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early‐stage HNSCC patients receive minimally invasive surgery or irradiation alone, with good outcomes, while late‐stage patients receive aggressive therapy, such as expanded surgery and/or concomitant chemoradiotherapy, resulting in dismal survival rates and poor quality of life . Screening for HNSCC depends on clinical symptoms and imaging examinations (laryngoscopy, computed tomography, magnetic resonance imaging, and positron emission tomography) and histopathological examination; however, owing to the non‐specificity of symptoms in early‐stage disease and ineffective conventional cancer‐related biomarkers, the early detection of HNSCC remains unsatisfactory. As they occur early in carcinogenesis and have other advantageous characteristics, abnormal methylation patterns represent potential markers for early detection of cancer and can even be non‐invasively detected in various body fluids (blood, bronchial aspirates, brushing, saliva, and urine) .…”

Section: Discussionmentioning

confidence: 99%

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

Zhou

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundThe purpose of the current study was to assess the association between HOXA9 (homeobox A9) promoter methylation and head and neck squamous cell carcinoma (HNSCC) and its diagnostic value.MethodsQuantitative methylation‐specific PCR (qMSP) was applied to measure HOXA9 promoter methylation levels in 145 paired HNSCC and corresponding normal tissue samples. Data from the Cancer Genome Atlas (TCGA) database (n = 578; 528 HNSCC and 50 normal) were also analyzed.ResultsSignificantly higher levels of HOXA9 promoter methylation were detected in HNSCC, compared with normal, tissues (our cohort: P = 1.06E‐35; TCGA cohort: P = 3.06E‐39). Moreover, HOXA9 methylation was significantly increased in patients with advanced tumor (T) stage, lymph node metastasis, and advanced clinical stage. Areas under the receiver characteristic curves (AUCs) based on our cohort and TCGA data were 0.930 and 0.967, respectively.ConclusionIn summary, our study reveals that HOXA9 promoter hypermethylation contributes to the risk of HNSCC and its progression and metastasis. Additionally, HOXA9 hypermethylation is a potential biomarker for the early diagnosis and screening of patients with HNSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

Zhou

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The screening for HNSCC depends on clinical symptoms and imaging examinations such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) [101]. However, because of nonspecific symptoms in the early stage and lack of effective diagnostic biomarkers, a low early diagnostic rate brings challenges for effective treatment.…”

Section: Discussionmentioning

confidence: 99%

The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis

Zhou

Shen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: The association between cyclin-dependent kinase inhibitor 2A (CDKN2A) hypermethylation and head and neck squamous cell carcinoma (HNSCC) risk has been investigated by a number of studies. However, these studies have not demonstrated consistent results. Moreover, the role of CDKN2A methylation in HNSCC carcinogenesis and its clinical significance remain unclear. Methods: We performed a systematic meta-analysis based on 72 articles (including 3399 HNSCCs, 668 premalignant lesions, and 2393 normal controls) from the PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure and Wanfang databases. Results: Our study showed a significant increase in the frequency of CDKN2A methylation during HNSCC carcinogenesis (HNSCC vs. normal controls, odds ratio (OR) = 6.72, P < 0.01; HNSCC vs. precancerous lesions, OR = 1.89, P < 0.05; precancerous lesions vs. normal controls, OR = 14.70, P < 0.01). Moreover, CDKN2A methylation was significantly associated with gender (OR = 1.34; P < 0.05) and lymph node metastasis (OR = 2.32; P < 0.01). The area under summary receiver operating characteristic curve (AUC) for diagnosis of HNSCC based on all samples and saliva sample subgroup were 0.77 and 0.96, respectively. Additionally, CDKN2A hypermethylation was significantly associated with shorter overall survival (OS) (hazard ratio (HR) = 1.01, P < 0.05) and recurrence-free survival (RFS) (HR = 1.77, P < 0.05). Conclusion: Our findings indicate CDKN2A methylation is involved in the carcinogenesis, progression, and metastasis of HNSCC. Furthermore, methylated CDKN2A could be a potential diagnostic and prognostic biomarker for HNSCC.

show abstract

“…However, the sensitivity and specificity of imaging techniques are unsatisfactory [ 34 , 35 ], and very few patients with laryngeal cancer are diagnosed through conventional imaging techniques [ 3 ]. Biopsy remains the gold standard for diagnosing laryngeal cancer [ 36 ]. This approach, however, is limited due to its invasiveness, and is not suitable for large-scale screening.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundClaudin-11 (CLDN11) is frequently silenced by its promoter hypermethylation. Previous studies have shown that CLDN11 promoter hypermethylation is a potential biomarker for diagnosing various cancers. The aim of this study was to investigate CLDN11 promoter methylation and its potential relevance to clinicopathologic features and prognosis of patients with laryngeal squamous cell carcinoma (LSCC).Material/MethodsUsing the quantitative methylation-specific polymerase chain reaction (qMSP), CLDN11 promoter methylation was measured in 91 tumor tissues and their paired adjacent normal tissues, and the relationship between CLDN11 methylation and clinicopathologic features was evaluated. A receiver operating characteristic (ROC) curve was created to assess diagnostic values, and the Kaplan-Meier survival analysis was used to evaluate the association between CLDN11 methylation and prognosis of patients with LSCC.ResultsOur results showed significantly elevated promoter methylation of CLDN11 in tumor tissues compared to their adjacent tissues (p=1.227E-16). CLDN11 promoter methylation also increased in patients with lymph node metastasis (p=0.009), advanced clinical stage (p=9.26E-06) and higher T classification (p=0.003). The area under the ROC curve (AUC) of CLDN11 was 0.884 (95% CI=0.835–0.932, p<0.01). The Kaplan-Meier analysis indicated that high CLDN11 promoter methylation levels were associated with poor overall survival of LSCC patients (log-rank test, p=0.007).ConclusionsWe demonstrated that CLDN11 promoter hypermethylation is a frequent event in LSCC, and contributes to metastasis and progression of LSCC. Thus, CLDN11 could be a potential biomarker for diagnosis and prognosis of LSCC patients.

show abstract

Diagnosis of laryngeal carcinoma

Cited by 7 publications

References 33 publications

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma

The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis

The Clinical Signification of Claudin-11 Promoter Hypermethylation for Laryngeal Squamous Cell Carcinoma

Contact Info

Product

Resources

About